
Investors in Denali Therapeutics Inc (DNLI) can explore options strategies for yield enhancement, as highlighted by a recent analysis. Selling a $15.00 strike put, 9% out-of-the-money, offers an annualized 16.45% return on cash commitment with a 70% chance of expiring worthless, effectively lowering the entry price to $13.35. Alternatively, a covered call strategy with a $17.50 strike could yield a 17.72% total return by June 2026, or an annualized 17.25% premium boost if the call expires worthless, with implied volatilities for these options at 79% and 73% respectively.
The analysis presents two options strategies for Denali Therapeutics Inc (DNLI), currently trading at $16.48/share, aimed at yield enhancement or discounted entry. Selling a $15.00 strike put, approximately 9% out-of-the-money, offers a $1.65 premium, effectively reducing the entry price to $13.35 if assigned. This strategy yields an 11.00% return on cash commitment, or 16.45% annualized, with a 70% probability of the put expiring worthless. Alternatively, a covered call strategy using a $17.50 strike call, about 6% out-of-the-money, provides a $1.90 premium. This could result in a 17.72% total return by June 2026 if the stock is called away, or an 11.53% premium boost (17.25% annualized) if the call expires worthless, an event with a 40% probability. The implied volatility for the put contract is 79% and for the call contract is 73%, both significantly higher than DNLI's trailing twelve-month actual volatility of 63%. This disparity suggests robust options premiums, potentially favoring options sellers. However, the covered call strategy inherently caps potential upside gains if DNLI shares experience a substantial rally beyond the strike price.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment